Testing effectiveness (Phase 2)WithdrawnNCT06050954
What this trial is testing
A Pilot Study of Circulating Tumor DNA Adaptive Risk Maintenance Approach for Bladder Cancer (CARMA)
Who this might be right for
Metastatic Urothelial Carcinoma
Fox Chase Cancer Center